Genedata Extends Lead Discovery Collaboration with Novartis
News May 16, 2006
Genedata’s agreement with Novartis includes round the clock support for the Genedata Screener® platform in Cambridge (MA), USA and Basel, Switzerland.
"Novartis sought an innovative partner to deliver advanced analysis and visualization tools for HTS analysis," explained Dr. Stephan Heyse, Head of Screener.
The collaboration with Genedata was initiated with Novartis Discovery Technologies, a core component of the NIBR.
Novartis cultivates close development partnerships through its Discovery Technologies program.
Successful collaborations are scaled-up and applied at the Company’s research sites globally.
Scientists at Novartis use Screener to pinpoint quality issues in screening data as part of a highly automated analysis workflow. The software is designed to validate entire screens in a standardized fashion.
Dr. Heyse added, "This saves time and minimizes the risk that lead compounds fail at later phases of drug development."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE